N
← Back to Search
Sponsored

Accelerate Your Clinical Trial Recruitment

Reach thousands of high-intent patients matching your specific inclusion criteria.

Start Campaign
RECRUITING Phase 2 ClinicalTrials.gov

A Study to Assess Change in Disease Activity and Adverse Events in Adult Participants With Gynecologic Cancers Receiving Intravenous Infusion of IMGN151 as Monotherapy or in Combination With Other Therapies

Sponsor: AbbVie • ClinicalTrials.gov ID: NCT07024784

Registry updated: 2026-10-01
Ad

Recruiting for Similar Conditions?

Sponsors are looking for patients like you. See if you qualify for compensated research studies.

Check Eligibility →

Description

Cancer is a condition where cells in a specific part of body grow and reproduce uncontrollably. The purpose of this study is to assess safety and tolerability of IMGN151 when given as monotherapy and in combination with other anti-cancer therapies in adult participants with gynecologic cancers. IMGN151 is an investigational drug being developed for the treatment of gynecologic cancers. Participants are placed in 1 of 4 groups, called treatment arms. Each group receives a different treatment. Around 377 participants with gynecologic cancers will be enrolled in the study at approximately 50 sites worldwide. Participants will receive intravenous infusions of IMGN151 as monotherapy or in combination with anti-cancer therapies according to their assigned study arm. In Arm A, participants will receive IMGN151 in combination with carboplatin on Day 1 of each cycle. In Arm B, participants will receive IMGN151 in combination with olaparib, twice a day (BID) on Day 1 of each cycle. In Arm C, participants will receive IMGN151 in combination with bevacizumab on Day 1 of each cycle. In Arm D, participants will receive IMGN151 as monotherapy on Day 1 of each cycle. In Arm E, participants will receive IMGN151 as monotherapy on Day 1 of each cycle. In Arm F, participants will receive IMGN151 as monotherapy on Day 1 of each cycle. The total study duration will be approximately 3 years. There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at a hospital or clinic and may require frequent medical assessments, blood tests, and scans.

Interventions

  • IMGN151 (Drug)
    Intravenous (IV) infusion
  • Carboplatin (Drug)
    Intravenous (IV) infusion
  • Bevacizumab (Drug)
    Intravenous (IV) infusion
  • Olaparib (Drug)
    Oral Tablet

Eligibility criteria

Inclusion Criteria: * ECOG performance status of 0 or 1 * Participants (except for platinum-sensitive ovarian, fallopian tube, and primary peritoneal cancer (PSOC) participants without disease progression after platinum combination standard of care therapy in Arms B and D) will have ≥ 1 lesion that meets the definition of measurable disease by RECIST v1.1 (radiographically measured by the investigator). * Participants will have high-grade serous epithelial ovarian, fallopian tube, and primary peritoneal cancers (EOC). * Participant has completed prior therapy within the specified times below: * Systemic antineoplastic therapy within 5 half-lives or 4 weeks (whichever is shorter) prior to the first dose of IMGN151. * Focal radiation completed ≥ 2 weeks prior to the first dose of study treatment. Exclusion Criteria: * Participants with ovarian cancer with histologies including: endometrioid, clear cell, mucinous, or sarcomatous histology, mixed tumors containing any of the above histologies, as well a low-grade or borderline ovarian tumor. * History of clinically significant medical conditions or any other reason that the investigator determines would interfere with the participant's participation in this study or would make the participant an unsuitable candidate to receive study treatment. * Prior treatment with FRα-targeting therapy. * Prior wide-field radiotherapy affecting more than 20% of the bone marrow.

Conditions

Gynecologic Cancers Platinum-Sensitive Ovarian Cancer Fallopian Tube Cancer Primary Peritoneal Cancer (PSOC)

Locations

  • Start Los Angeles /ID# 281533 — Los Angeles, California, United States
  • University of Colorado Hospital- Aurora /ID# 278232 — Aurora, Colorado, United States
  • University Of Minnesota /ID# 277850 — Minneapolis, Minnesota, United States
  • Holy Name Medical Center /ID# 279017 — Teaneck, New Jersey, United States
  • SUNY Upstate Medical University - Syracuse /ID# 277305 — Syracuse, New York, United States
  • University of Cincinnati Medical Center. /ID# 278925 — Cincinnati, Ohio, United States
  • University Hospitals Cleveland Medical Center /ID# 279601 — Cleveland, Ohio, United States
  • OU Health - Stephenson Cancer Center /ID# 277656 — Oklahoma City, Oklahoma, United States
  • Providence Portland Medical Center /ID# 277727 — Portland, Oregon, United States
  • Women & Infants Hospital /ID# 277930 — Providence, Rhode Island, United States
  • SCRI Oncology Partners /ID# 279733 — Nashville, Tennessee, United States
  • Texas Oncology-Austin North /ID# 279958 — Austin, Texas, United States
  • Next Virginia /ID# 279684 — Fairfax, Virginia, United States
  • Rabin Medical Center /ID# 279142 — Petah Tikva, Central District, Israel
  • The Chaim Sheba Medical Center /ID# 275997 — Ramat Gan, Tel Aviv, Israel
  • Tel Aviv Sourasky Medical Center /ID# 275852 — Tel Aviv, Tel Aviv, Israel
  • Rambam Health Care Campus- Haifa /ID# 276004 — Haifa, Israel
  • Shaare Zedek Medical Center /ID# 275854 — Jerusalem, Israel
  • Hyogo Cancer Center /ID# 276940 — Akashi-shi, Hyōgo, Japan
  • National Cancer Center Hospital /ID# 276715 — Chuo-Ku, Tokyo, Japan
  • The Cancer Institute Hospital Of Japanese Foundation for Cancer Research /ID# 276711 — Koto-ku, Tokyo, Japan
Sponsored

Partner with Nurenyx

Showcase your study to thousands of motivated patients matching your criteria.

Learn More

Official Source

Data sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

View Official Record